









市場行情
/
股票
/
nasdaq-bntc
/

Benitec Biopharma Inc

BNTC

12.960USD

+0.610+4.94%

收盤 12/23, 16:00（美東）報價延遲15分鐘

340.21M總市值

虧損本益比TTM



Benitec Biopharma Inc

12.960

+0.610+4.94%

概覽公司財務分析

概覽

公司

財務

分析

關於 Benitec Biopharma Inc 公司

Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.

Benitec Biopharma Inc簡介



公司代碼BNTC

公司名稱Benitec Biopharma Inc

上市日期Jul 11, 2012

CEOBanks (Jerel A)

員工數量19

證券類型Ordinary Share

年結日Jul 11

公司地址3940 Trust Way

城市HAYWARD

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編94545

電話15107800819

網址https://benitec.com/

公司代碼BNTC

上市日期Jul 11, 2012

CEOBanks (Jerel A)

Benitec Biopharma Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Ms. Megan Joan Boston

Chief Financial Officer, Executive Director, Secretary

25.93K

Ms. Sophie Mukadam

Chief Operating Officer

6.02K

Mr. Peter Damian Francis

Independent Director

297.00

Buchi (J Kevin)

Independent Director

Mr. Kishan (Kishen) Mehta

Independent Director

Dr. Sharon Mates, Ph.D.

Independent Director

Ms. Irina Koffler

Managing Director

Dr. Jerel A. Banks, M.D., Ph.D.

Executive Chairman of the Board, Chief Executive Officer

Mr. Edward F. Smith

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Ms. Megan Joan Boston

Chief Financial Officer, Executive Director, Secretary

25.93K

Ms. Sophie Mukadam

Chief Operating Officer

6.02K

Mr. Peter Damian Francis

Independent Director

297.00

Buchi (J Kevin)

Independent Director

Mr. Kishan (Kishen) Mehta

Independent Director

Dr. Sharon Mates, Ph.D.

Independent Director

收入明細

單位: USD更新時間: 7月6日週日

FY2023

FY2022

FY2021

FY2019

業務USD

名稱

營收

佔比

Licensing revenue

75.00K

0.00%

由於公司未披露，未能獲取相關數據

業務

地區

業務USD

名稱

營收

佔比

Licensing revenue

75.00K

0.00%

股東統計

更新時間: 12月5日週五

持股股東

股東類型

持股股東

佔比

Suvretta Capital Management, LLC

33.54%

Janus Henderson Investors

8.60%

Franklin Advisers, Inc.

7.65%

Adage Capital Management, L.P.

5.83%

RA Capital Management, LP

5.46%

其他

38.92%

持股股東

佔比

Suvretta Capital Management, LLC

33.54%

Janus Henderson Investors

8.60%

Franklin Advisers, Inc.

7.65%

Adage Capital Management, L.P.

5.83%

RA Capital Management, LP

5.46%

其他

38.92%

股東類型

持股股東

佔比

Hedge Fund

44.05%

Investment Advisor/Hedge Fund

19.90%

Investment Advisor

11.78%

Venture Capital

5.46%

Corporation

2.20%

Research Firm

0.61%

Individual Investor

0.53%

Bank and Trust

0.04%

Insurance Company

0.02%

其他

15.40%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

104

27.71M

70.75%

+3.33M

2025Q3

104

24.38M

91.26%

+455.37K

2025Q2

100

23.88M

84.92%

+1.54M

2025Q1

22.35M

78.36%

+2.34M

2024Q4

20.11M

70.30%

+3.66M

2024Q3

14.59M

41.10%

+7.39M

2024Q2

7.24M

58.15%

+2.08M

2024Q1

1.32M

57.31%

-243.94K

2023Q4

1.24M

60.74%

-70.36K

2023Q3

1.31M

59.46%

+42.18K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Suvretta Capital Management, LLC

9.88M

37.62%

Jun 30, 2025

Janus Henderson Investors

2.90M

11.06%

-16.16K

-0.55%

Jun 30, 2025

Franklin Advisers, Inc.

2.70M

10.29%

-159.28K

-5.57%

Jun 30, 2025

Adage Capital Management, L.P.

1.97M

7.51%

Jun 30, 2025

HBM Partners AG

1.04M

3.97%

+200.27K

+23.80%

Dec 31, 2024

The Vanguard Group, Inc.

969.17K

3.69%

+642.13K

+196.35%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

661.64K

2.52%

+477.75K

+259.80%

Jun 30, 2025

Nantahala Capital Management, LLC

838.10K

3.19%

Jun 30, 2025

Nemean Asset Management, LLC

746.32K

2.84%

+648.12K

+659.98%

Apr 22, 2024

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Simplify Health Care ETF

1.08%

iShares Neuroscience and Healthcare ETF

0.53%

iShares Micro-Cap ETF

0.05%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.02%

iShares Russell 2000 Growth ETF

0.01%

Global X Russell 2000 ETF

0.01%

Proshares Ultra Russell 2000

0.01%

Invesco Russell 2000 Dynamic Multifactor ETF

0.01%

ProShares UltraPro Russell2000

0.01%

ProShares Hedge Replication ETF

0.01%

Simplify Health Care ETF

佔比1.08%

iShares Neuroscience and Healthcare ETF

佔比0.53%

iShares Micro-Cap ETF

佔比0.05%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

佔比0.02%

iShares Russell 2000 Growth ETF

佔比0.01%

Global X Russell 2000 ETF

佔比0.01%

Proshares Ultra Russell 2000

佔比0.01%

Invesco Russell 2000 Dynamic Multifactor ETF

佔比0.01%

ProShares UltraPro Russell2000

佔比0.01%

ProShares Hedge Replication ETF

佔比0.01%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Jul 25, 2023

Merger

17→1

Jul 25, 2023

Merger

17→1

Jul 25, 2023

Merger

17→1

Jul 25, 2023

Merger

17→1

公告日期

類型

比率

Jul 25, 2023

Merger

17→1

Jul 25, 2023

Merger

17→1

Jul 25, 2023

Merger

17→1

Jul 25, 2023

Merger

17→1

常見問題

Benitec Biopharma Inc的前五大股東是誰？



Benitec Biopharma Inc的前五大股東如下：
Suvretta Capital Management, LLC
持有股份：9.88M
佔總股份比例：37.62%。
Janus Henderson Investors
持有股份：2.90M
佔總股份比例：11.06%。
Franklin Advisers, Inc.
持有股份：2.70M
佔總股份比例：10.29%。
Adage Capital Management, L.P.
持有股份：1.97M
佔總股份比例：7.51%。
HBM Partners AG
持有股份：1.04M
佔總股份比例：3.97%。